Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSAD87)

Drug Name

N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide Drug Info

Synonyms

N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide; CHEMBL378980; SCHEMBL1145050; BDBM15960; Aminopyridine-Based Inhibitor 19d

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Investigative Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting JNK2 messenger RNA (JNK2 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide	DMUFVM6	Discovery agent	N.A.	Investigative	[1]
AS-601245	DMQ95EB	Discovery agent	N.A.	Investigative	[2]
Aminopyridine deriv. 2	DM94KQP	Discovery agent	N.A.	Investigative	[1]
IN-1166	DMMS6D3	Discovery agent	N.A.	Investigative	[3]
N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide	DMY1FMG	Discovery agent	N.A.	Investigative	[1]
JNK-IN-8	DMLWYJB	Discovery agent	N.A.	Investigative	[4]
AC1LG8KT	DMFKV97	Discovery agent	N.A.	Investigative	[5]
ISIS 18078	DMHZPJ0	Solid tumour/cancer	2A00-2F9Z	Investigative	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Drug(s) Targeting Stress-activated protein kinase JNK1 (JNK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NKP-1339	DM5AWK1	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[8]
PMID25991433-Compound-F2	DM37VIQ	N. A.	N. A.	Patented	[8]
7-azaindole derivative 1	DMQL5B7	N. A.	N. A.	Patented	[8]
7-azaindole derivative 5	DMV3H98	N. A.	N. A.	Patented	[8]
PMID25991433-Compound-P6	DMNDVC9	N. A.	N. A.	Patented	[8]
PMID25991433-Compound-J3	DM17P3F	N. A.	N. A.	Patented	[8]
PMID25991433-Compound-P1	DMD8AX6	N. A.	N. A.	Patented	[8]
PMID25991433-Compound-O3	DMVOWS5	N. A.	N. A.	Patented	[8]
PMID25991433-Compound-L1	DM2135Y	N. A.	N. A.	Patented	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
JNK2 messenger RNA (JNK2 mRNA)	TT3IVG2	MK09_HUMAN	Inhibitor	[1]
Stress-activated protein kinase JNK1 (JNK1)	TT0K6EO	MK08_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
2	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
3	Synthesis and biological evaluation of 4(5)-(6-alkylpyridin-2-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors. J Med Chem. 2007 Jun 28;50(13):3143-7.
4	Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54.
5	N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1296-301.
6	US patent application no. 7,425,545, Modulation of C-reactive protein expression.
7	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1496).
8	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.